权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Einstein/Rwanda/DRC Consortium for Research in HIV/HPV/ Malignancies

爱因斯坦/卢旺达/刚果民主共和国艾滋病毒/HPV/恶性肿瘤研究联盟

基本信息

批准号：
10267220
负责人：
Kathryn M. Anastos
金额：
$ 8.34万
依托单位：
ALBERT EINSTEIN COLLEGE OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-21 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10267220
关键词：
AIDS related cancer Address Africa Africa South of the Sahara Antibody titer measurement Bioinformatics Biological Assay Cancer Etiology Collaborations Congo Consent Data Democratic Republic of the Congo Development Disease Doctor of Philosophy Enzyme-Linked Immunosorbent Assay Epidemic Fostering Funding Funding Opportunities Genotype Geography Goals HIV HIV Infections HPV-High Risk Histopathology Human Microbiome Human Papilloma Virus-Related Malignant Neoplasm Human Papillomavirus Human Resources Human papilloma virus infection Human papillomavirus 16 Human papillomavirus 18 Immunoglobulin G Incidence Individual Infection Investigation Kaposi Sarcoma Laboratories Laboratory Research Lead Leadership Malignant Neoplasms Malignant neoplasm of anus Measurement Measures Military Hospitals Molecular Diagnostic Testing Non-Hodgkin&apos s Lymphoma Pathology Patients Persons Preventative vaccination Protocols documentation Research Research Infrastructure Research Personnel Research Project Grants Resource Sharing Resources Rwanda Sampling Serology System Teaching Hospitals Testing Time Translational Research Universities University Hospitals Viral Viral Load result Woman aged anticancer research antiretroviral therapy base cervical and anal cancer men who have sex with men microbiome analysis microbiome research microbiota molecular diagnostics molecular pathology next generation sequencing tool virus related cancer young woman

项目摘要

PROJECT SUMMARY Sub-Saharan Africa carries a disproportionate burden of HIV, with 69% of infections globally, as well as a high burden of virally induced malignancies, even before the HIV epidemic. Currently a third of all cancers in Sub- Saharan Africa are virally induced. While data from Africa are scant, evidence from other parts of the world indicates that with increasing rates of treatment with combination antiretroviral therapy for persons living with HIV (PLWH), the incidence of HIV-associated malignancies (i.e., Kaposi’s Sarcoma, non-Hodgkin’s Lymphoma) has declined dramatically. However, cancers caused by human papillomavirus (HPV), specifically invasive cervical cancer and anal cancer, have not declined and may have increased. Investigations of HPV-related malignancies are heavily dependent on laboratory testing and histopathology, which can be implemented in resource limited settings. The Rwanda/DRC/Einstein HIV-Associated HPV- Malignancies Research Center (HAMRC) proposed in this application will extend both the geographic and the scientific scope of our research and capacity-building activities. We will leverage our existing HIV research partnerships in the Democratic Republic of Congo (DRC) to include much desired research capacity to assess HPV-related cancers in PLWH. The Center proposes major studies of HPV-related malignancies through two projects: 1) evaluating the impact of HPV prophylactic vaccination in young women living with HIV; and 2) assessing HPV infection and disease in Congolese (DRC) and Rwandan men who have sex with men with and without HIV infection. In both studies we will investigate the interactions of HPV infection and disease with the local microbial flora. The Shared Resources Core addresses the goal of the HAMRC by fostering sustainable research capacity in Rwanda and the DRC to support investigation of viral-associated cancers. Thus, the specific aims of the Shared Resources Core are to provide rigorous molecular diagnostic analyses to support studies of the impact of both HAMRC projects, and to increase capacity to conduct research in HPV-related malignancies in PLWH in Rwanda and the DRC, and will specifically: 1. Replicate in the Pathology Laboratory at Université Protestante au Congo, the real-time PCR platform for hrHPV typing previously established at Rwanda Military Hospital (RMH), in the Einstein/RMH Research Laboratory. 2. Develop at the Rwanda Military Hospital (RMH), in the Einstein/RMH Research Laboratory, and in collaboration with the University of Rwanda, next generation sequencing. 3. Support further development of ELISA testing in Rwanda, at the Einstein/RMH Research Laboratory, using an assay to measure anti-HPV16 and HPV18 IgG antibody titers implementing a protocol established by the Frederick National Laboratory of Cancer Research HPV Serology Laboratory. The proposed capacity building will include personnel development of both research staff and investigators and will efficiently leverage existing research infrastructure previously developed in large part by the efforts of the proposed HARMC leadership.

项目总结